In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Related Pages

Leukemia - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

Immunotoxin Therapy for Treatment-Resistant Hairy Cell Leukemia
(Posted: 03/12/2014) - In this trial, patients with hairy cell leukemia who have relapsed multiple times or not responded to prior chemotherapy will be treated with an experimental immunotoxin called moxetumomab pasudotox given intravenously on days 1, 3, and 5 of 28-day cycles.

Treating Multiply Relapsed or Refractory Hairy Cell Leukemia
(Posted: 02/22/2011) - In this trial, patients with hairy cell leukemia who have not responded to initial chemotherapy followed by second-line treatment with rituximab, or who have relapsed following two courses of chemotherapy, will be randomly assigned to receive rituximab combined with either pentostatin or bendamustine.

Eliminating Hairy Cell Leukemia Minimal Residual Disease
(Posted: 10/19/2010) - In this trial, patients with hairy cell leukemia who have disease-related symptoms that require treatment, and who have not been treated or have had only one prior treatment with cladribine, will be randomly assigned to receive cladribine with either concurrent rituximab or rituximab at least 6 months after completing cladribine therapy.

Vaccine Therapy for Patients with Recurrent Blood Cancers
(Posted: 05/04/2010) - In this phase I/II trial, patients with blood cancer that has recurred after allogeneic stem cell transplantation will be treated with donor T-lymphocyte infusions and a dendritic cell vaccine that is designed to trigger an immune response against cells producing a protein called Wilms tumor 1 (WT1).

Extending Targeted Immune Depletion to Unrelated Cord Blood Transplantation
(Posted: 03/09/2010) - In this pilot study, patients with leukemia, lymphoma, multiple myeloma, or certain premalignant blood disorders (such as myelodysplastic syndromes) will undergo targeted immune-depleting chemotherapy followed by unrelated double cord blood transplant.

1 2 3 4 5 6  Next >